Emergency Curative Resection of Colorectal Cancer
- Conditions
- Oncologic Complications and EmergenciesColorectal Cancer
- Registration Number
- NCT04288284
- Lead Sponsor
- University of Alexandria
- Brief Summary
The feasibility and efficacy of emergency curative resection of complicated colorectal cancer is still controversial. This prospective study aim is to assess surgical and oncologic outcomes after emergency compared to elective curative resection of colorectal cancer
- Detailed Description
60 consecutive patients presented with complicated colorectal cancer managed by emergency surgery were included and compared to another 155 consecutive patients admitted during the same period with uncomplicated colorectal cancer managed by elective surgery. Both groups were compared regarding curative resection rate, early postoperative mortality and morbidity, 3-years tumor recurrence and survival rates.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 215
- All patients presented with Potentially operable colorectal cancer
- No clinical or radiological evidence of metastatic disease
- Patients received preoperative chemoradiation
- Patients with clinical or radiological evidence of metastatic disease
- Patients with intraoperative evidence of metastatic disease
- Patients with intraoperative evidence of irresectable disease
- Patients with incomplete follow up
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method early postoperative morbidity after curative resection of colorectal cancer within 90 days after surgery surgery-related complications
early postoperative mortality after curative resection of colorectal cancer within 90 days after surgery early death due to cause related to surgery
Adequate oncologic resection histopathological assessment of surgical specimens within 2 weeks postoperative Negative resection margins + adequate lymphadenectomy ( Lymph Nodes retrieved \> 12)
- Secondary Outcome Measures
Name Time Method Disease free survival By the end of the 3 years follow up period % of patients survived without recurrence
Overall survival By the end of the 3 years follow up period % of all patients survived either with or without recurrence
Tumor recurrence By the end of the 3 years follow up period either local or distant